Markets:

Overview

News

Currencies

International

Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

316.36 +2.32 (+0.74%)

Streaming Delayed Price Updated: 3:37 PM EDT, Jun 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum

January 06, 2023

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗

December 23, 2022

Via Benzinga

Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗

December 23, 2022

Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market...

Via Benzinga

Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says ↗

December 16, 2022

Credit Suisse initiated coverage on OmniAb Inc (NASDAQ: OABI) with an Outperform rating and a price target of $13.

Via Benzinga

Ligand Pharma Issues Mixed Guidance For FY23 ↗

December 13, 2022

At its Investor and Analyst Day event, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided an overview of Ligand's corporate structure and business following the successful spin-off of its...

Via Benzinga

Ligand Provides Highlights from its Investor and Analyst Day Event

December 13, 2022

From Ligand Pharmaceuticals

Via Business Wire

Ligand Pharmaceuticals Names Director Todd C. Davis as CEO

December 05, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Hold Investor and Analyst Day on December 13

November 16, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Reports Third Quarter 2022 Financial Results

November 07, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Earnings Outlook For Ligand Pharmaceuticals ↗

November 04, 2022

Ligand Pharmaceuticals (NASDAQ:LGND) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Ligand...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 02, 2022

Gainers Monopar Therapeutics (NASDAQ:MNPR) shares increased by 53.0% to $4.09 during Wednesday's pre-market session. The company's market cap stands at $52.0 million.

Via Benzinga

Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗

November 01, 2022

October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...

Via Benzinga

Ligand Announces Completion of OmniAb Spin-Off

November 01, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Distribution of OmniAb Complete and Business Combination Closed

November 01, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Third Quarter Financial Results on November 7

October 26, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

October 26, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

OmniAb Business Combination Approved by APAC Shareholders

October 24, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

October 03, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients ↗

August 25, 2022

Via Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary ↗

August 24, 2022

Via Benzinga

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

August 24, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals: Q2 Earnings Insights ↗

August 08, 2022

Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q2 earnings results on Monday, August 8, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Ligand Pharmaceuticals...

Via Benzinga

Ligand Reports Second Quarter 2022 Financial Results

August 08, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

August 01, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Ligand to Report Second Quarter Financial Results on August 8

July 22, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

Barclays Maintains Overweight Rating for Ligand Pharmaceuticals: Here's What You Need To Know ↗

July 05, 2022

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00. Shares of Ligand Pharmaceuticals are trading up 1.79%...

Via Benzinga

Ligand Pharmaceuticals Appoints Jason Haas to its Board of Directors

June 29, 2022

From Ligand Pharmaceuticals Incorporated

Via Business Wire

10 Biggest Price Target Changes For Monday ↗

May 16, 2022

Needham cut the price target on Carvana Co. (NYSE: CVNA) from $121 to $80. Carvana shares rose 11.3% to $42.71 in pre-market trading.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.